Response and palliation in a phase II trial of gemcitabine in hormone-refractory metastatic prostatic carcinoma. Swiss Group for Clinical Cancer Research (SAKK).

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples